News

These Investors Search for ‘Extreme Winners.’ Why Aurora, BYD, Tempus AI Make the Cut.
Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection
AstraZeneca’s AI algorithms, developed based on biomarkers and diagnosis data points, have shown promise in broadening the ...
Sell Tempus AI Stock Before The Cooldown Hits
Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...
kedglobal2d
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca
Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI-powered lung cancer diagnostics market. Ken Nesmith ...
Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
Tempus AI, Inc. is revolutionizing healthcare genomics with AI and data partnerships. Click here to read an analysis on TEM ...
Equity Insider: From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 20, 2025 /PRNewswire/ -- Equity Insider News Commentary - The World Economic ...
TMCnet4d
From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
Analysts forecast explosive growth ahead for AI in healthcare, with MarketsandMarkets projecting the market to surge past $110 billion by 2030 on a 38.6% compound annual growth rate. Accenture goes ...